Thanks for these wonderful updates, [~ @yale.edu] ! We encourage other members of the community to comment on the implications and clinical relevance of these findings/studies.

It's a small study, and not all patients had been on ribociclib, so many questions remain. Is the benefit due to switching endocrine therapy? Switching CDK4/6i? Both? It's also a small study that paves the way for larger phase III trials, but it is certainly provocative.